Tag: FDA 2 results

Rare Disease

Accelerated Approval: Planning for Confirmatory Trials

FDA’s Accelerated Approval Program creates an opportunity to bring promising treatments for serious conditions to patients sooner. Yet the pathway introduces a consequential planning challenge: the evidence that supports initial approval and the evidence required to verify clinical benefit must...

Consulting

FDA’s Drug Repurposing Push Puts 505(b)(2) Strategy in Focus 

The U.S. Food and Drug Administration’s (FDA) renewed focus on drug repurposing is bringing fresh attention to a regulatory pathway that has quietly shaped drug development for decades: 505(b)(2). Starting out as a critical mechanism bridging the gap between traditional 505(b)(1) new drug applications and abbreviated...